Ascletis Pharma Inc.
1672
Rank in Stocks
#10435
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Share Price
$0.75890907
Market Cap
$796.59M
Change (1 day)
3.53%
Change (1 year)
-37.79%
Country
CN
Trade Ascletis Pharma Inc. (1672)
Category
Healthcare
Stock price history for Ascletis Pharma Inc. (1672)
Highest end of day price: $0.92 on 2026-10-01
Lowest end of day price: $0.60 on 2019-11-01
Lowest end of day price: $0.60 on 2019-11-01
Stock price history of Ascletis Pharma Inc. from 2019 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -10.79% |
| 2025 | 759.36% |
| 2024 | 9.90% |
| 2023 | -65.45% |
| 2022 | 11,939.80% |
| 2021 | -98.81% |
| 2020 | -40.55% |
| 2019 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
